Effects of serotonergic drugs on immune checkpoint inhibitor response: a pooled analysis of individual patient data from four Canadian Cancer Trials Group (CCTG) trials
Use of serotonergic drugs did not impact PFS or OS in patients treated with dual ICI ± chemotherapy. This study supports the safe use of serotonergic drugs in the context of dual ICI therapy.
Authors
- Daniel J. Renouf (ORCID: https://orcid.org/0000-0002-7597-6089)
- Keyue Ding (ORCID: https://orcid.org/0000-0002-3496-6415)
- Rosalyn A. Juergens (ORCID: https://orcid.org/0000-0001-8627-4704)
- Desirée Hao (ORCID: https://orcid.org/0000-0003-1727-1205)
- Natasha B. Leighl (ORCID: https://orcid.org/0000-0002-3249-4602)
- Courtney H. Coschi
- Francisco Vera-Badillo (ORCID: https://orcid.org/0000-0003-1068-3258)
- Lesley Seymour (ORCID: https://orcid.org/0000-0001-8081-0799)
- Christopher O’Callaghan (ORCID: https://orcid.org/0000-0002-8633-2473)
- Dongsheng Tu (ORCID: https://orcid.org/0000-0003-4842-2184)
- Eric X. Chen (ORCID: https://orcid.org/0000-0002-4581-8848)
- Andrea S. Fung (ORCID: https://orcid.org/0000-0002-2031-6921)
- Pierre-Olivier Gaudreau
Institutions
- Queen's University (CA)
- Juravinski Cancer Centre (CA)
- Princess Margaret Cancer Centre (CA)
- Victorian Comprehensive Cancer Centre (AU)
- Pancreas Centre (Canada) (CA)
- McMaster University (CA)
Publication Details
- Journal
- Immunotherapy
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1080/1750743x.2025.2578164
- Primary Topic
- Cancer, Stress, Anesthesia, and Immune Response
- Type
- article
- Field-Weighted Citation Impact
- 0.00